ST. PETERSBURG, Fla. -- Veridien Corporation announces that it has entered into a three-year group purchasing contract with MedAssets for its patented Viraguard infection control products. MedAssets is a supply chain solutions company that improves it member's cash flow. MedAssets membership encompasses more than 2,400 hospitals and 24,000 total healthcare facilities located in all 50 states and the District of Columbia.
Paul Dunnigan, vice president of the Marketing Group, said, "Veridien is looking forward to supplying MedAssets members with the Viraguard infection control products. MedAssets is the first completely national purchasing agreement for Veridien in the GPO arena. Our products are ideal for long-term care services, hospitals, and all areas of healthcare. Viraguard's new Heavy Duty Textured Wipes are superb for disinfection in all types of facilities and for home care providers. We expect that MedAssets members will provide growing sales and outstanding awareness of Viraguard infection control products in both the hospital and alternate-care arenas."
John Kautzer, director of distribution and patient care services/materials management contract director of MedAssets, said, "At our recent New Technologies Forum, the Veridien product line scored extremely well with our membership that participated. MedAssets is dedicated to sourcing the finest products at the best prices to our members. We are proud to bring Viraguard into our product portfolio as a premium line of surface disinfectants and hand antiseptics for our healthcare professionals. This is especially important as this product line has better kill claims than the current competition, and is safer for the healthcare provider and the environment. We look forward to a long and beneficial relationship with Veridien."
Source: Veridien Corporation
Â
Uncovering a Hidden Risk: Alcohol Use Disorder Significantly Increases C difficile Infection Rates
April 10th 2025A groundbreaking study reveals a strong connection between alcohol use disorder and increased risk for Clostridioides difficile infection, challenging traditional assumptions and calling for enhanced infection prevention protocols.